​
​

Dianthus Therapeutics Ownership 2024 | Who Owns Dianthus Therapeutics Now?

OverviewForecastRevenueFinancialsChart

Insider Ownership

8.83%

Dianthus Therapeutics Mutual Fund Holders

Name% Total AssetsTotal SharesChange AmountChange %Date
FIDELITY ADVISOR SERIES VII0.02%197,696--Jan 31, 2024
FIDELITY CAPITAL TRUST0.01%92,121--Jan 31, 2024
FIDELITY SECURITIES FUND0.00%240,326--Jan 31, 2024
VANGUARD INDEX FUNDS0.00%508,683332,708189.07%Mar 31, 2024
VANGUARD VALLEY FORGE FUNDS0.00%265--Mar 31, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS0.00%10,047-2,603-20.58%Mar 31, 2024
SCHWAB CAPITAL TRUST0.00%1,710--Jan 31, 2024
ALLIANZ VARIABLE INSURANCE PRODUCTS TRUST0.00%902--Dec 31, 2023
Dimensional ETF Trust0.00%4,6954,695-Jan 31, 2024
DFA INVESTMENT DIMENSIONS GROUP INC0.00%7,2805,319271.24%Jan 31, 2024
AMERICAN CENTURY ETF TRUST0.00%740740-Feb 29, 2024
USAA MUTUAL FUNDS TRUST0.00%1,434-3,763-72.41%Jan 31, 2024
WILSHIRE MUTUAL FUNDS INC0.00%441441-Dec 31, 2023
iSHARES TRUST0.00%10,835200.18%Mar 31, 2024
Advisors' Inner Circle Fund III0.00%3232-Jan 31, 2024
JOHN HANCOCK VARIABLE INSURANCE TRUST0.00%297-881-74.79%Mar 31, 2024

Dianthus Therapeutics's largest mutual fund holder by % of total assets is "FIDELITY ADVISOR SERIES VII", owning 197.70K shares, compromising 0.02% of its total assets.

Dianthus Therapeutics Insider Shareholders Trades

Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Apr 01, 2024Fairmount Funds Management LLCdirector-J-OtherSell58,857---

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
May 28, 2024CARR EDWARDofficer CHIEF ACCOUNTING OFFICERA-AwardBuy60,000$21.77$1.31M60,000
May 28, 2024Veness Adam Mofficer SVP, General Counsel and Sec.A-AwardBuy75,000$21.77$1.63M75,000
May 28, 2024Randhawa Simratofficer CHIEF MEDICAL OFFICERA-AwardBuy100,000$21.77$2.18M100,000
May 28, 2024Savitz Ryanofficer CFO & CBOA-AwardBuy100,000$21.77$2.18M100,000
May 28, 2024Garcia Marinodirector, officer CEO AND PRESIDENTA-AwardBuy243,000$21.77$5.29M243,000
May 28, 2024Violin Jonathandirector-A-AwardBuy11,000$21.77$239.47K11,000
May 28, 2024Soteropoulos Pauladirector-A-AwardBuy11,000$21.77$239.47K11,000
May 28, 2024MOULDER LEON O JRdirector-A-AwardBuy11,000$21.77$239.47K11,000
May 28, 2024McGeorge Annedirector-A-AwardBuy11,000$21.77$239.47K11,000
May 28, 2024Lawton Alison Francesdirector-A-AwardBuy11,000$21.77$239.47K11,000
May 28, 2024Fairmount Funds Management LLCdirector-A-AwardBuy11,000$21.77$239.47K11,000
Apr 01, 2024Fairmount Funds Management LLCdirector-J-OtherBuy58,857--2,700,691
Apr 01, 2024Fairmount Funds Management LLCdirector-J-OtherSell58,857---
Jan 26, 2024CARR EDWARDofficer CHIEF ACCOUNTING OFFICERA-AwardBuy80,000$17.88$1.43M80,000
Jan 26, 2024Veness Adam Mofficer SVP, General Counsel and Sec.A-AwardBuy110,000$17.88$1.97M110,000
Jan 26, 2024Randhawa Simratofficer CHIEF MEDICAL OFFICERA-AwardBuy120,000$17.88$2.15M120,000
Jan 26, 2024Savitz Ryanofficer CHIEF FINANCIAL OFFICERA-AwardBuy120,000$17.88$2.15M120,000
Jan 26, 2024Garcia Marinodirector, officer CEO AND PRESIDENTA-AwardBuy275,000$17.88$4.92M275,000
Jan 24, 2024MOULDER LEON O JRdirector-A-AwardBuy166,667$12.00$2.00M1,436,745
Jan 24, 2024Fairmount Funds Management LLCdirector, 10 percent owner A-AwardBuy834,334$12.00$10.01M2,762,837

The last insider sell of Dianthus Therapeutics's stock was made by Fairmount Funds Management LLC on Apr 01 2024, selling 58,857 shares at - per share (valued at -).

Dianthus Therapeutics Insider Ownership Trends

All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q2 202411100.00%
Q1 202410--
Q3 20236--

1 total buy trades, and 1 total sell trades (buy/sell ratio of 1.00%) were made by Dianthus Therapeutics's insiders, as of Q2 2024.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q2 2024---
Q1 2024---
Q3 20235--

As of Q2 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Dianthus Therapeutics's stocks.

DNTH Ownership FAQ